Moberg Pharma AB (publ)
The answer first
Does Moberg Pharma beat the market?
No, Moberg Pharma has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 52% of Nordic stocks
- Quality80
- Value31
- Trend48
No. 57 of 195 in healthcare
Max for seven days
Follow Moberg Pharma with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Moberg Pharma
Your first answer is free, no account needed.
Do you own Moberg Pharma, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Moberg Pharma and a few more. Free, no card.
Super Stock+45.9%In short
- Moberg Pharma has risen 14.5% over the past year, including dividends.
- Overall, Moberg Pharma ranks better than 52% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 86.9%. The price is 97.8% below its peak now.
What do analysts think of Moberg Pharma?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 52% of Nordic stocks.
No. 57 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 53 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.00
- Asset turnoverSales divided by everything the company owns0.03
- Return on equityProfit divided by equity−2.9%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 73 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity0.7
- P/SPrice divided by sales25.0
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 73 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−12.5%
- 6 months−5.0%
- 9 months+6.6%
- 12 months+14.5%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Moberg Pharma
3 funds we follow own Moberg Pharma. The share is how much of the fund the stock makes up.
- Sweden3
From the funds' latest known holdings.
About Moberg Pharma
Moberg Pharma AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 5 employees.
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.


See the full analysis of Moberg Pharma.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card